About Vaccinogen
Vaccinogen: Turning Cancer On Itself Through OncoVAX® Immunotherapy
Vaccinogen is an industry leading patient-specific immunotherapy company with Phase III data demonstrating that OncoVAX® reduces Stage 2 colon cancer recurrence from one in three patients to one in nine. Vaccinogen expects to begin enrolling patients in an international Phase IIIb confirmatory study (ACTIVE) in a larger group of patients who will receive patient-specific OncoVAX® doses processed with a patented, proprietary process.
Vaccinogen has developed an innovative, logistically efficient manufacturing process that makes personalized, sterile, tumor-based cancer immunotherapy a viable option for cancer patients worldwide. The process is a major asset of the company and is patented with a length of exclusivity of 17 years. The patent, “Autologous tumor vaccines and methods” patent number 11/351/235 was issued on 06/07/2022.
OncoVAX® represents an opportunity to fundamentally change cancer treatment because it is not a single drug, or even a colon cancer-specific product. OncoVAX® is a process which could potentially be applied to different tumor types. Previous studies have also determined that these clinical investigations will allow for further translational research: the isolation and characterization of cancer-specific, human monoclonal antibodies. These human antibodies, (HuMab), can be the guide to a group of specific neoepitopes, tumor antigens, which may be protective immunotherapy of all immunotherapeutics for all adenocarcinomas. This future research approach is in a pending patent and can become the offshoot of the Cellular Phase IIIB clinical trial.
